Eckert & Ziegler SE (MIL:1EUZ) LT-Debt-to-Total-Asset : 0.09 (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Eckert & Ziegler SE LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Eckert & Ziegler SE's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.09.

Eckert & Ziegler SE's long-term debt to total assets ratio declined from Sep. 2023 (0.10) to Sep. 2024 (0.09). It may suggest that Eckert & Ziegler SE is progressively becoming less dependent on debt to grow their business.

Eckert & Ziegler SE LT-Debt-to-Total-Asset Historical Data

The historical data trend for Eckert & Ziegler SE's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eckert & Ziegler SE LT-Debt-to-Total-Asset Chart

Eckert & Ziegler SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.06

0.05

0.12

0.11

Eckert & Ziegler SE Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.10	0.11	0.10	0.10	0.09

Eckert & Ziegler SE LT-Debt-to-Total-Asset Calculation

Eckert & Ziegler SE's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	47.356	/	439.364
	=	0.11

Eckert & Ziegler SE's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	42.7	/	480.919
	=	0.09

Eckert & Ziegler SE (MIL:1EUZ) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Eckert & Ziegler SE LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Eckert & Ziegler SE's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Eckert & Ziegler SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Eckert & Ziegler SE (MIL:1EUZ) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

EUZd:UK 0NZY:UK EUZ:Germany EUZ:Germany EUZ:Germany EUZ:Germany

Address

Robert-Rossle-Street 10, Berlin, BB, DEU, 13125

Website

https://www.ezag.com

Eckert & Ziegler SE is a provider of isotope technology for medical, scientific, and industrial use. It is predominantly engaged in the business of cancer therapy, industrial radiometry, and nuclear medical imaging. The company's segments are Medical, Isotope Products, and Other. The Isotope Products segment which generates key revenue, manufactures and distributes standards and radiation sources for medical and industrial purposes. The Medical segment provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. The Other segment comprises the items of the holding company. Geographically, the company generates a majority of its revenue from Europe and the rest from North America, Asia/Pacific, and other regions.

Eckert & Ziegler SE Headlines

No Headlines